Article

FDA Accepts NDA for Gefapixant for Chronic Cough

Author(s):

The application, submitted by Merck, is based on data from 2 clinical trials evaluating patients with refractory or unexplained chronic cough.

FDA

The US Food and Drug Administration (FDA) has accepted Merck’s New Drug Application (NDA) for gefapixant—an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults.

“This submission underscores our commitment to help patients with refractory or unexplained chronic cough who currently have limited treatment options,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories in a statement.

“If approved by the FDA, gefapixant would be the first medicine approved specifically to help these patients, and we look forward to participating in the advisory committee meeting and working with the FDA as they review our application,” he continued.

Currently, no date for an advisory committee meeting has been scheduled, but the FDA has set a Prescription Drug User Fee Act (PDUFA), or target action date, of Dec. 21, 2021.

Clinical Trials

The NDA is based on results from the Phase 3 COUGH-1 and COUGH-2 clinical trials, which are the first dual studies to evaluate patients with RCC or UCC.

The multinational, randomized, double-blind, placebo-controlled studies assessed a combined total of 2044 participants (COUGH-1, n = 730; COUGH-2, n = 1314).

Patients were then randomly assigned to receive gefapixant 45 mg twice daily, gefapixant 15 mg twice daily, or placebo.

The primary efficacy outcome measures were 24-hour cough frequency at week 12 for COUGH-1 and 24-hour cough frequency at week 24 for COUGH-2. Frequency was measured using an ambulatory digital audio recording device.

As such, data presented at the Virtual European Respiratory Society (ERS) International Congress 2020 showed that gefapixant 45 mg significantly reduced 24-hour cough frequency versus placebo at 12 weeks (-18.45% [95% CI, -32.92 to -0.86, P = 0.041]) in COUGH-1.

This trend was also seen in COUGH-2. Gefapixant demonstrated a significant reduction at 24 weeks compared with placebo (-14.64% [95% CI, -26.07 to -1.43; P = 0.031]).

However, gexapixant 15 mg did not meant the primary efficacy endpoint in either Phase 3 study.

Related Videos
How to Manage Aspirin-Exacerbated Respiratory Disease
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
MeiLan Han, MD: Discussing Updates on Dupilumab, Ensifentrine in 2025 GOLD Report
How Artificial Intelligence is Being Used in Lung Imaging, with Rachel Eddy, PhD
Developing Risk Assessment Tools for Viruses in School
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
What Do Patients Need to Learn About their Hypersensitivity Pneumonitis?
Discussing Use of Vaping Among Students, Conversations About Vaccines
© 2024 MJH Life Sciences

All rights reserved.